Lung cancer in China: current and prospect : Current Opinion in Oncology Lung cancer in
China: current and prospect : Current Opinion in Oncology Log in or Register Subscribe to …

Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …

Background Intrahepatic cholangiocarcinoma (ICC) is a malignant carcinoma with high rate
of mortality. The current treatment is ineffective with poor survival time. Therefore, there is an …

Purpose Anlotinib is widely used in the clinical treatment of non-small cell lung cancer
(NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to …

Lung cancer is one of the cancers with the highest incidence in the world, and there is no
standard treatment plan after second-line progression. Tumor angiogenesis has now been …

Purpose As for local advanced non-small cell lung cancer (NSCLC), synchronous
radiotherapy and chemotherapy is the standard treatment mode. But for patients with …

Multitargeted antiangiogenic drugs have demonstrated significant antitumor activity against
a variety of solid tumors. Anlotinib, a novel oral multitargeted antiangiogenic tyrosine kinase …

Background In ALTER 1202, anlotinib prolonged the progression-free survival (PFS) and
overall survival (OS) of patients with relapsed small cell lung cancer (SCLC). The aim of this …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Objective: The purpose of this study is to evaluate the efficacy and safety of anlotinib in
patients with advanced non-small cell lung cancer (NSCLC) who had previously received …